NO20071490L - Farmasoytisk aktive isoindolderivater - Google Patents

Farmasoytisk aktive isoindolderivater

Info

Publication number
NO20071490L
NO20071490L NO20071490A NO20071490A NO20071490L NO 20071490 L NO20071490 L NO 20071490L NO 20071490 A NO20071490 A NO 20071490A NO 20071490 A NO20071490 A NO 20071490A NO 20071490 L NO20071490 L NO 20071490L
Authority
NO
Norway
Prior art keywords
pharmaceutically active
isoindole derivatives
relates
isomer
compound
Prior art date
Application number
NO20071490A
Other languages
English (en)
Other versions
NO336210B1 (no
Inventor
Hon-Wah Man
George Muller
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20071490L publication Critical patent/NO20071490L/no
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of NO336210B1 publication Critical patent/NO336210B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Oppfinnelsen vedrører en forbindelse, kjennetegnet ved formelen: eller en optisk isomer derav. Oppfinnelsen vedrører også anvendelse av en i det vesentlige kiral, ren (R)- eller (S)-isomer av forbindelsen ifølge krav 1 eller en blanding av nevnte isomerer ved framstilling av et medikament. Oppfinnelsen vedrører også et farmasøytisk preparat, kjennetegnet ved at det omfatter en i det vesentlige ki ral, ren (R)- eller (S)-isomer av en forbindelse ifølge krav 1 eller en blanding av nevnte isomerer; og en farmasøytisk akseptabel bærer.
NO20071490A 1999-11-12 2007-03-21 Farmasøytisk aktive isoindolderivater, anvendelse derav samt farmasøytisk preparat omfattende et slikt derivat. NO336210B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16516899P 1999-11-12 1999-11-12
US59034400A 2000-06-08 2000-06-08
US09/708,199 US6667316B1 (en) 1999-11-12 2000-11-08 Pharmaceutically active isoindoline derivatives
PCT/US2000/030770 WO2001034606A1 (en) 1999-11-12 2000-11-09 Pharmaceutically active isoindoline derivatives

Publications (2)

Publication Number Publication Date
NO20071490L true NO20071490L (no) 2002-07-08
NO336210B1 NO336210B1 (no) 2015-06-15

Family

ID=27389110

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20022223A NO323633B1 (no) 1999-11-12 2002-05-08 Farmasoytisk aktive isoindolderivater
NO20071490A NO336210B1 (no) 1999-11-12 2007-03-21 Farmasøytisk aktive isoindolderivater, anvendelse derav samt farmasøytisk preparat omfattende et slikt derivat.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20022223A NO323633B1 (no) 1999-11-12 2002-05-08 Farmasoytisk aktive isoindolderivater

Country Status (19)

Country Link
US (1) US6667316B1 (no)
EP (4) EP2255801B1 (no)
JP (1) JP5116201B2 (no)
CN (1) CN1325497C (no)
AT (4) ATE506058T1 (no)
AU (2) AU782409B2 (no)
CA (1) CA2392081C (no)
CY (2) CY1107610T1 (no)
DE (1) DE60034139T2 (no)
DK (2) DK2263669T3 (no)
ES (4) ES2380574T3 (no)
FI (1) FI119931B (no)
HK (1) HK1049158A1 (no)
MX (1) MXPA02004793A (no)
NO (2) NO323633B1 (no)
NZ (1) NZ519459A (no)
PT (2) PT1228071E (no)
SI (1) SI1228071T1 (no)
WO (1) WO2001034606A1 (no)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429221B1 (en) 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US6518281B2 (en) * 1995-08-29 2003-02-11 Celgene Corporation Immunotherapeutic agents
ES2315435T3 (es) * 1996-08-12 2009-04-01 Celgene Corporation Nuevos agentes inmunoterapeuticos y su uso para la reduccion de los niveles de citoquinas.
US8030343B2 (en) * 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
US7491634B2 (en) * 2006-04-28 2009-02-17 Asm International N.V. Methods for forming roughened surfaces and applications thereof
CA2444704C (en) 2001-04-23 2012-07-10 University Of Virginia Patent Foundation Synthesis and evaluation of phthalimide mimics as anti-angiogenic agents
WO2003014315A2 (en) * 2001-08-06 2003-02-20 The Children's Medical Center Corporation Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US8263637B2 (en) * 2002-05-17 2012-09-11 Celgene Corporation Methods for treatment of multiple myeloma using cyclopropane carboxylic acid {2-[(is)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 h-isoindol-4-yl}-amide
US7842691B2 (en) 2002-10-15 2010-11-30 Celgene Corporation Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide
US20040087558A1 (en) 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
EP1567148A4 (en) * 2002-10-31 2010-09-15 Celgene Corp METHOD OF USE AND COMPOSITIONS WITH SELECTIVE CYTOKINE INHIBITORS FOR THE TREATMENT AND SUPPLEMENT OF MACULAR DEGENERATION
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
BR0316002A (pt) * 2002-11-06 2005-09-13 Celgene Corp Métodos de tratar ou prevenir e controlar uma doença mieloproliferativa, de reduzir ou evitar de um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doença mieloproliferativa, composição farmacêutica e kit
EP1567154A4 (en) * 2002-11-06 2006-05-31 Celgene Corp METHODS AND COMPOSITIONS USING CYTOKINE SELECTIVE INHIBITION DRUGS FOR TREATING AND CONTROLLING CANCERS AND OTHER DISEASES
BR0316256A (pt) * 2002-11-18 2005-10-04 Celgene Corp Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
WO2004045597A1 (en) * 2002-11-18 2004-06-03 Celgene Corporation Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
CA2511843C (en) 2002-12-30 2012-04-24 Celgene Corporation Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses
KR100831545B1 (ko) * 2003-03-06 2008-05-21 셀진 코포레이션 중추 신경계 장애의 치료 또는 관리를 위한 선택적사이토카인 억제 약물의 사용 방법 및 그를 포함하는조성물
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
CN100427465C (zh) * 2003-03-12 2008-10-22 细胞基因公司 N-烷基-异羟肟酸-异吲哚基化合物及其药物用途
ZA200507284B (en) * 2003-03-12 2007-03-28 Celgene Corp 7-amino-isoindolyl compounds and their pharmaceutical uses
DE602004032522D1 (de) * 2003-03-12 2011-06-16 Celgene Corp Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
EP1613269B1 (en) 2003-04-04 2015-02-25 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
JP2007524656A (ja) * 2003-10-23 2007-08-30 セルジーン・コーポレーション 疼痛を治療、改変および管理するための選択的サイトカイン阻害薬を含む組成物ならびにその使用方法
US20050142104A1 (en) * 2003-11-06 2005-06-30 Zeldis Jerome B. Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
CA2563207A1 (en) * 2004-04-14 2005-11-24 Celgene Corporation Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
BRPI0510166A (pt) * 2004-04-23 2007-10-02 Celgene Corp método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica
MXPA06012701A (es) * 2004-05-05 2007-02-14 Celgene Corp Metodo de utilizacion y composiciones que comprenden farmacos inhibidores de citocina selectivos para el tratamiento y manejo de enfermedades mieloproliferativas.
AU2004319815A1 (en) * 2004-05-05 2005-12-01 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
WO2006004191A1 (en) * 2004-07-05 2006-01-12 Astellas Pharma Inc. Pyrrolopyridazine derivatives which inhibit pde iv and tnf alfa
US7244759B2 (en) * 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
BRPI0514857A (pt) * 2004-09-03 2008-05-06 Celgene Corp composto ou um sal, solvato ou hidrato farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos para inibir a angiogênese, para inibir ou reduzir a polimerização da tubulina ou a estabilidade da tubulina em uma célula, para inibir a atividade de pde4 em uma célula, para inibir atividade do fator-alfa de necrose de tumor (tnf-alfa) em uma célula, para tratar ou melhorar um distúrbio inflamatório, para tratar ou melhorar cáncer, para inibir a proliferação de célula cancerosa, para marcar, bloquear ou destruir a função de vasculatura tumoral, para marcar, bloquear ou destruir o endotélio de vasos tumor, para marcar, bloquear ou destruir a função de vasculatura tumoral e inibir a angiogênese em um tumor e para tratar ou melhorar um distúrbio do sistema nervoso central
JP2008518924A (ja) * 2004-10-28 2008-06-05 セルジーン・コーポレーション 中枢神経系損傷の治療及び管理のためのｐｄｅ４モジュレータを使用する方法及び組成物
JP2008523102A (ja) * 2004-12-13 2008-07-03 セルジーン・コーポレーション Ｐｄｅ４モジュレーターを含有する組成物及び気道炎症の治療又は予防のためのそれらの使用
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
EP2268279A1 (en) * 2008-03-24 2011-01-05 Celgene Corporation Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl¨-3-oxoisoindoline-4-yl}carboxamide
EP2344479B1 (en) * 2008-09-23 2015-04-08 Georgetown University 1,2-benzisothiazolinone and isoindolinone derivatives
US8563580B2 (en) * 2008-09-23 2013-10-22 Georgetown University Flavivirus inhibitors and methods for their use
CN102387798A (zh) 2009-02-10 2012-03-21 细胞基因公司 供治疗、预防和控制结核病的pde4调节剂的使用方法及包含其的组合物
CN108059635B (zh) * 2009-05-14 2021-10-01 天津合美医药科技有限公司 噻吩衍生物
US8124646B2 (en) 2009-06-18 2012-02-28 Concert Pharmaceuticals, Inc. Substituted isoindoline-1,3-dione derivatives
AU2010303243B2 (en) * 2009-10-09 2014-08-28 Celgene Corporation Processes for the preparation of 2-(1-phenylethyl) isoindolin-1-one compounds
AU2010333767A1 (en) * 2009-12-22 2012-07-05 Celgene Corporation (Methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
JP5937060B2 (ja) 2010-04-07 2016-06-22 セルジーン コーポレイション 呼吸器ウイルス感染症の治療方法
JP2013531499A (ja) 2010-06-15 2013-08-08 セルジーン コーポレイション 乾癬の治療のためのバイオマーカー
MX347928B (es) * 2011-01-10 2017-05-19 Celgene Corp Derivados de fenetilsulfona isoindolina y su uso.
MX2013007959A (es) * 2011-01-10 2013-12-06 Celgene Corp Formas farmaceuticas orales de amida {2-[(1s)-1-(3-etoxi-4-metoxi- fenil]-2-metansulfonil-etil]-3-oxo-2,,3-dihidro-1h-isoindol -4-il}-del acido ciclopropancarboxilico.
WO2012097116A2 (en) 2011-01-14 2012-07-19 Celgene Corporation Isotopologues of isoindole derivatives
JP2014511393A (ja) * 2011-03-07 2014-05-15 セルジーン コーポレイション イソインドリン化合物を用いた疾患の治療方法
CA2845551C (en) 2011-08-16 2020-06-09 Georgetown University Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives
JP2014526508A (ja) * 2011-09-14 2014-10-06 セルジーン コーポレイション シクロプロパンカルボン酸｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシ−フェニル）−２−メタンスルホニル−エチル］−３−オキソ−２，３−ジヒドロ−１ｈ−イソインドール−４−イル｝−アミドの製剤
US8981117B2 (en) 2012-09-14 2015-03-17 Celgene Corporation Processes for the preparation of isoindole compounds and isotopologues thereof
US20170087129A1 (en) 2014-05-16 2017-03-30 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
JP6687550B2 (ja) 2014-06-23 2020-04-22 セルジーン コーポレイション 肝疾患又は肝機能異常を治療するためのアプレミラスト
BR112017019850A2 (pt) * 2015-03-19 2018-06-05 Cipla Ltd ?processo melhorado para a preparação de apremilast?
US10682336B2 (en) 2015-10-21 2020-06-16 Amgen Inc. PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS)
HU231259B1 (hu) 2016-02-04 2022-06-28 Egyt Gyogyszervegyeszeti Gyar Eljárás pomalidomide elõállítására
JP7029444B2 (ja) * 2016-08-22 2022-04-07 メッドシャイン ディスカバリー インコーポレイテッド Ｐｄｅ４阻害剤
CN107698484B (zh) * 2017-11-13 2020-05-19 广东中科药物研究有限公司 一种来那度胺的衍生物的制备方法与应用
WO2019142124A1 (en) 2018-01-17 2019-07-25 Cadila Healthcare Limited Pharmaceutical compositions for treatment of vitiligo
JP7535995B2 (ja) 2018-04-17 2024-08-19 天津合美医▲薬▼科技有限公司 イソインドール誘導体
CN110746376B (zh) * 2018-07-22 2024-04-30 上海星叶医药科技有限公司 苯并异硒唑酮胺类化合物及其制备方法和用途
CN110003084B (zh) * 2019-03-15 2022-08-02 华南师范大学 一种同时具有力致发光和聚集诱导发光特性的有机圆偏振发光材料及其制备方法与应用
CN111170925B (zh) * 2020-01-09 2023-01-17 常州大学 作为pde2/4双重抑制剂的邻苯二甲酰亚胺类化合物及其制备方法
CA3201965A1 (en) * 2020-12-14 2022-06-23 Kyle W.H. Chan Pde4 degraders, pharmaceutical compositions, and therapeutic applications
AU2022240650B2 (en) * 2021-03-15 2025-01-30 Shenzhen Forward Pharmaceuticals Co., Limited Estrogen receptor antagonist
CN114790164B (zh) 2021-08-13 2022-12-27 苏州璞正医药有限公司 一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途
CN116354857B (zh) * 2023-03-01 2025-01-21 中国人民解放军海军军医大学 一种β-氨基砜及其衍生物的制备方法
CN120000646A (zh) * 2023-11-14 2025-05-16 天津合美医药科技有限公司 干燥综合征的预防或治疗
WO2025103426A1 (zh) * 2023-11-14 2025-05-22 赣州和美药业股份有限公司 白塞综合征的治疗

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4173652A (en) 1976-12-18 1979-11-06 Akzona Incorporated Pharmaceutical hydroxamic acid compositions and uses thereof
SE434638B (sv) 1980-06-06 1984-08-06 Lekemedelsfabriken Medica Ab Nya terapeutiska verdefulla taurinderivat och deras framstellning
US4820828A (en) 1987-03-04 1989-04-11 Ortho Pharmaceutical Corporation Cinnamohydroxamic acids
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5605914A (en) 1993-07-02 1997-02-25 Celgene Corporation Imides
US5703098A (en) 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
US5801195A (en) 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
CN1090614C (zh) 1995-07-26 2002-09-11 辉瑞大药厂 N－(芳酰基)甘氨酸异羟肟酸衍生物及相关化合物
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US5728845A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
US5658940A (en) 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
ES2217386T3 (es) 1996-01-02 2004-11-01 Aventis Pharmaceuticals Inc. Compuestos de acido(aril, heteroaril, arilmetil o heteroarilmetil) hidroxamico sustituido.
WO1998005635A1 (en) * 1996-08-07 1998-02-12 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
ES2315435T3 (es) 1996-08-12 2009-04-01 Celgene Corporation Nuevos agentes inmunoterapeuticos y su uso para la reduccion de los niveles de citoquinas.
US6214857B1 (en) * 1997-07-31 2001-04-10 Celgene Corporation Substituted alkanohydroxamic acids and method of reducing TNFα levels
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels

Also Published As

Publication number Publication date
NO323633B1 (no) 2007-06-18
NO20022223D0 (no) 2002-05-08
DK2263669T3 (da) 2012-04-23
FI20020892A0 (fi) 2002-05-10
ATE544452T1 (de) 2012-02-15
HK1049158A1 (zh) 2003-05-02
NO20022223L (no) 2002-07-08
EP2255801B1 (en) 2012-02-08
NZ519459A (en) 2003-11-28
JP2004500346A (ja) 2004-01-08
ATE544451T1 (de) 2012-02-15
DE60034139T2 (de) 2007-12-06
ES2282147T3 (es) 2007-10-16
CN1325497C (zh) 2007-07-11
AU2005202964B2 (en) 2007-11-22
AU782409B2 (en) 2005-07-28
EP2255801A1 (en) 2010-12-01
US6667316B1 (en) 2003-12-23
JP5116201B2 (ja) 2013-01-09
DE60034139D1 (de) 2007-05-10
PT2263669E (pt) 2012-04-23
WO2001034606A1 (en) 2001-05-17
CA2392081C (en) 2010-01-05
ES2380574T3 (es) 2012-05-16
EP1228071A1 (en) 2002-08-07
ES2363933T3 (es) 2011-08-19
NO336210B1 (no) 2015-06-15
EP1698334A1 (en) 2006-09-06
EP1228071B1 (en) 2007-03-28
EP1698334B1 (en) 2011-04-20
FI119931B (fi) 2009-05-15
HK1053467A1 (en) 2003-10-24
EP1228071A4 (en) 2002-12-04
ES2381174T3 (es) 2012-05-23
EP2263669B1 (en) 2012-02-08
CA2392081A1 (en) 2001-05-17
PT1228071E (pt) 2007-05-31
ATE357913T1 (de) 2007-04-15
MXPA02004793A (es) 2003-10-14
EP1228071B8 (en) 2012-02-29
CN1420889A (zh) 2003-05-28
CY1107610T1 (el) 2013-03-13
AU2005202964A1 (en) 2005-08-11
ATE506058T1 (de) 2011-05-15
FI20020892L (fi) 2002-06-20
SI1228071T1 (sl) 2007-08-31
AU1478001A (en) 2001-06-06
CY1112707T1 (el) 2016-02-10
DK1228071T3 (da) 2007-08-06
EP2263669A1 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
NO20071490L (no) Farmasoytisk aktive isoindolderivater
NO20071498L (no) Substituerte acylhydroksamsyrer samt fremgangsmate for a redusere TNFa-nivaet
IS2750B (is) Leiðarafesting
DK0562956T3 (da) Hidtil ukendte naphthylalkylaminer, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
ATE106860T1 (de) R-enantiomer von n-propargyl-1-aminoindan, dessen herstellung und dieses enthaltende pharmazeutische zusammensetzungen.
DK0527687T3 (da) Hidtil ukendte arylethylaminderivater, fremgansmåder til fremstilling heraf og farmaceutiske midler, som indeholder dem
EA200200571A1 (ru) Новая композиция и ее применение
SE9901875D0 (sv) Novel compounds
NO20043367L (no) Oralt farmasoytisk preparat
ATE386725T1 (de) Heterocyclylverbindungen
NO304113B1 (no) Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament
PA8426801A1 (es) Composiciones farmaceuticas para el tratamiento de la rinitis.
EE05085B1 (et) Pridiin-1-oksiidderivaat ja meetod selle muutmiseks farmatseutiliselt efektiivseteks henditeks
PT1233953E (pt) Novos derivados de benzotiadiazinas processo para a sua preparacao e as composicoes farmaceuticas que os contem
SE0102440D0 (sv) New compound
DE69330601D1 (de) Serotoninergische ergolin derivate
CA2344686A1 (en) High purity composition comprising (7.alpha.,17.alpha.)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
FR2756826B1 (fr) Nouveaux derives tetrahydropyridiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU656674B2 (en) New thiochroman compounds, processes for the preparation thereof, and pharmaceutical compositions containing them
RU94000064A (ru) Новые 2-циано-3-гидроксипропенамиды, метод их получения и содержащие их фармацевтические композиции
SE9900190D0 (sv) New compounds
SE9902742D0 (sv) New pharmaceutical formultion
BR0213463A (pt) Composições farmacêuticas contendo macrólidos
DE60029946D1 (de) Arzneimittel gegen glomerulosclerose
IT1262565B (it) Disaccaridi di antracicline, loro processi di preparazione e composizioni farmaceutiche che li contengono.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees